Telix Pharmaceuticals Ltd has released a press release.
FDA Orphan Drug Designation for Bone Marrow Conditioning
Filed with ASX ·
Watch Telix Pharmaceuticals' latest callTelix Pharmaceuticals (ASX:TLX) Q2 2026 Earnings Call · Replay · Aug 20Read the transcript of Telix Pharmaceuticals (ASX:TLX) Q2 2026 Earnings Call6ix hasn’t read this filing yet.
Telix Pharmaceuticals Limited on 6ix
Story so far
Earlier from Telix Pharmaceuticals
- Telix and Xiel Sign U.K. and Ireland Distribution Agreement
- Development of Glioblastoma Therapy Program
- Radiopharmaceutical Production Facility Buildout Commences
- ZIRCON Phase 3 Imaging Study Completes Targets Enrolment
- Cancellation of Share Purchase Plan
Later from Telix Pharmaceuticals
- Commercial Launch - Illuccix Now Available to Order in US
- Telix, GMS & Monash Awarded $23 million Federal Funding
- Telix Enters Licence Agreement with Lilly for Olaratumab
- ProstACT TARGET Phase II Study Ethics Approval
- Appendix 4C and Activities Report for March 2022 quarter
Follow Telix Pharmaceuticals into a list and get an email when it puts out news.
Follow Telix Pharmaceuticals